Comparison between Basilic Fly Studio IPO and Mono Pharmacare IPO.
Basilic Fly Studio IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Mono Pharmacare IPO is a SME Bookbuilding proposed to list at NSE SME.
| Basilic Fly Studio IPO | Mono Pharmacare IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | NSE SME |
| Lead Managers | GYR Capital Advisors Pvt.Ltd. | Unistone Capital Pvt.Ltd. |
| Registrar | Purva Sharegistry (India) Pvt.Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Share India Securities Ltd. | Rikhav Securities Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Basilic Fly Studio IPO is up to ₹56.40 Cr whereas the issue size of the Mono Pharmacare IPO is up to ₹14.07 Cr. The final issue price of Basilic Fly Studio IPO is ₹97.00 per share and of Mono Pharmacare IPO is ₹28.00 per share.
| Basilic Fly Studio IPO | Mono Pharmacare IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹92.00 per share | ₹26.00 per share |
| Issue Price (Upper) | ₹97.00 per share | ₹28.00 per share |
| Issue Price (Final) | ₹97.00 per share | ₹28.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 1200 shares | 4000 shares |
| Fresh Issue Size | 52,14,000 shares | 50,24,000 shares |
| Fresh Issue Size (Amount) | up to ₹50.58 Cr | up to ₹14.07 Cr |
| OFS Issue Size | 6,00,000 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹5.82 Cr | up to ₹0.00 Cr |
| Issue Size Total | 58,14,000 shares | 50,24,000 shares |
| Issue Size Total (Amount) | up to ₹56.40 Cr | up to ₹14.07 Cr |
Basilic Fly Studio IPO opens on Sep 01, 2023, while Mono Pharmacare IPO opens on Aug 28, 2023. The closing date of Basilic Fly Studio IPO and Mono Pharmacare IPO is Sep 05, 2023, and Aug 30, 2023, respectively.
| Basilic Fly Studio IPO | Mono Pharmacare IPO | |
|---|---|---|
| Anchor Bid Date | Aug 31, 2023 | |
| Issue Open | Sep 01, 2023 | Aug 28, 2023 |
| Issue Close | Sep 05, 2023 | Aug 30, 2023 |
| Basis Of Allotment (Tentative) | Sep 11, 2023 | Sep 04, 2023 |
| Initiation of Refunds (Tentative) | Sep 12, 2023 | Sep 05, 2023 |
| Credit of Share (Tentative) | Sep 13, 2023 | Sep 06, 2023 |
| Listing date (Tentative) | Sep 11, 2023 | Sep 07, 2023 |
| Anchor Lockin End date 1 | Oct 11, 2023 | |
| Anchor Lockin End date 2 | Dec 10, 2023 |
Basilic Fly Studio IPO P/E ratio is 5.94, as compared to Mono Pharmacare IPO P/E ratio of .
| Basilic Fly Studio IPO | Mono Pharmacare IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 85.42 | 81.02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 5.94 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹225.43 Cr. | ₹49.47 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 155.63% | 9.01% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 104.73% | 10.34% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.14 | 2.92 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹16.32 | ₹1.99 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 87.59% | 9.01% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Basilic Fly Studio IPO Retail Individual Investors (RII) are offered 20,35,200 shares while in Mono Pharmacare IPO retail investors are offered 20,35,200 shares. Qualified Institutional Buyers (QIB) are offered 11,62,800 shares in Basilic Fly Studio IPO and 5,00,000 shares in Mono Pharmacare IPO.
| Basilic Fly Studio IPO | Mono Pharmacare IPO | |
|---|---|---|
| Anchor Investor Reservation | 17,43,600 shares | |
| Market Maker Reservation | 10,26,000 shares | 2,76,000 shares |
| QIB | 11,62,800 shares | 5,00,000 shares |
| NII | 8,72,400 shares | 22,60,000 shares |
| RII | 20,35,200 shares | 22,64,000 shares |
| Employee | ||
| Others | ||
| Total | 58,14,000 shares | 50,24,000 shares |
Basilic Fly Studio IPO subscribed 358.60x in total, whereas Mono Pharmacare IPO subscribed 13.42x.
| Basilic Fly Studio IPO | Mono Pharmacare IPO | |
|---|---|---|
| QIB (times) | 116.34x | 10.89x |
| NII (times) | 549.44x | 8.00x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 415.22x | 19.40x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 358.60x | 13.42x |
